Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis
NCT07546097Phase 4Recruiting
- Sponsor
- Yongquan Shi
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of upadacitinib in ulcerative colitis (UC) (2 arms), sponsored by Yongquan Shi. Primary endpoint: Clinical Response. Started Mar 2026; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07546097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07546097.